Hcyb1 |
| Catalog No.GC64012 |
Hcyb1 est un inhibiteur de PDE2 hautement sélectif et actif par voie orale.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Hcyb1 is a highly selective, orally active PDE2 inhibitor. Hcyb1 has a highly selective inhibition of PDE2A (IC50=0.57 μM) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 produces neuroprotective and antidepressant‐like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling[1].
Hcyb1 (1~100 nM; 10 minutes) increases cGMP levels by 1.7~2.3 folds[1].Hcyb1 (1 nM; 24 hours) increases both cGMP and cAMP levels[1].Hcyb1 (24 hours) treatment also increases the levels of phosphorylation of CREB and BDNF in HT-22 cells[1].Hcyb1 promotes HT-22 cell viability and increase the cGMP and cAMP accumulation in HT-22 cells[1].Hcyb1 exhibits the concentration- and time-dependent effects on cell viability in HT-22 cells[2].
Hcyb1 (0.5, 1, and 2 mg/kg, i.g.) decreases the immobility time in both forced swimming and tail suspension tests, without altering locomotor activity[3].
[1]. Li Liu, et al. The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor. CNS Neurosci Ther. 2018 Jul;24(7):652-660.
[2]. Meng-Jia Zhu, et al. Phosphodiesterase 2 inhibitor Hcyb1 reverses corticosterone-induced neurotoxicity and depression-like behavior. Psychopharmacology (Berl). 2020 Nov;237(11):3215-3224.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *